GGiantBullStocks

NovoCure Limited - Ordinary Shares (NVCR)

NASDAQ · Healthcare

$15.94+0.13%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$1.9B
P/E ratio
EPS
Volume
904,722
52-week high
52-week low
Open
$16.00
Day high
$16.19
Day low
$15.80

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025$655.35M-$136.23M-$1.22
2024$605.22M-$168.63M-$1.56
2023$509.34M-$207.04M-$1.95
2022$537.84M-$92.53M-$0.88
2021$535.03M-$58.35M-$0.56

About NovoCure Limited - Ordinary Shares

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

CEO
Frank Leonard
Employees
1,605
Country
CH
IPO date
Oct 2, 2015

Similar stocks

Other Healthcare companies

Frequently asked questions

What is NovoCure Limited - Ordinary Shares's stock price today?
NVCR is trading at $15.94 as of Jul 20, 2026.
What is NovoCure Limited - Ordinary Shares's market cap?
NovoCure Limited - Ordinary Shares (NVCR) has a market capitalization of $1.9B.
Does NovoCure Limited - Ordinary Shares pay a dividend?
NovoCure Limited - Ordinary Shares did not pay a dividend in its most recent reported fiscal year.
What sector is NovoCure Limited - Ordinary Shares in?
NovoCure Limited - Ordinary Shares operates in the Healthcare sector.